Novo Nordisk's Victoza gets EU market green light
COPENHAGEN, July 3 (Reuters) - Danish pharmaceuticals group Novo Nordisk's (NOVOb.CO: Quote, Profile, Research) diabetes treatment Victoza has won European Commission approval for marketing across the EU, the company said on Friday.
"The European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults," Novo Nordisk said in a statement, calling it an "important milestone."
The company will launch Victoza in the UK, Germany and Denmark this summer and in other European markets in the second half of 2009 and throughout 2010, it said.
"The marketing approval in Europe does not change Novo Nordisk's expectations for the company's financial results for 2009," it added.
© Thomson Reuters 2009 All rights reserved
UK joins G20 push for world levy on banks
Britain threw its weight behind proposals to impose a global levy on banks to fund future bailouts and called on the G20 to work toward a $100 billion deal to meet the cost of climate change. Full Article | Full Coverage
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article
India
US
UK
